RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300.
September 19, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a $300 price target by RBC Capital suggests positive sentiment and confidence in Alnylam's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100